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A Machine-Assisted Approach for the Preparation of Follow-on 
Pharmaceutical Compound Libraries  
Christiane Schotten, Lisa G. T. Leist, A. Lisa Semrau, Duncan. L. Browne*	
Follow-on drugs represent the majority of new drug introductions and show improved properties to 
the pioneer drug. In order to fast-follow, R&D needs to be able to quickly generate a library of 
analogues that can then be screened for desired properties. Here we have designed a hybrid machine-
assisted approach which makes use of both multi-step continuous flow processing and robotic 
microwave reactors to generate a library of indoles over two technology steps (four reaction steps; 
diazotization, reduction, unmasking of the hydrazine and Fischer indole reaction). This ‘machine’ is 
then used to prepare a small library of hitherto unreported analogues of the 5-HT agonist Zolmitriptan 
in good yields, thus demonstrating that the integration and use of machines is a powerful tool to 
expedite drug discovery.  
Introduction 
The discovery and development of new pharmaceutical 
compounds is crucial to the continued improvement of human 
health. The majority of new drug compounds introduced to the 
market consist of so called “follow-on” or “me-too” drugs. The 
term “me-too” refers to new compounds developed in parallel 
to the pioneer drug which do not necessarily show improved 
properties, whereas, the term “follow-on” usually refers to 
those compounds that are introduced after the pioneer drug. 
Follow-on compounds often exhibit improvements over the 
already approved pioneer drug, for example, through lowered 
dosing rates or weakened side effects. Follow-on compounds 
are either developed by the pharmaceutical company who 
introduced the original pioneering molecule or by a competing 
company aiming for a market share. Even though follow-on 
drugs have been criticised for not driving forward innovation in 
the same manner as pioneering drugs, they can increase 
availability of important pharmaceutical agents through 
lowering prices and raising the standard of medication through 
their enhanced properties.1 
Recently, the use of a machine-assisted approaches for the 
synthesis of compounds or compound collections with useful 
properties has been discussed and explored.2 Such approaches 
take advantage of automation, computer control and robotics 
to perform manual and repetitive operations and thus free-up 
human operators and minimize errors derived from repetitive 
tasks. Furthermore, integration of several reaction steps and/or 
workup processes can lead to decreased handling operations 
and streamline the synthesis process.  
Within the context of follow-on pharmaceutical compounds, we 
considered a continuous flow + robotic microwave hybrid 
machine. Such a hybrid would be capable of conducting 
multistep synthesis, including the generation and consumption 
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Figure 1. Examples of Triptan Drugs with marketing company 
and year of FDA approval 
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of hazardous materials on the front-end of the ‘machine’ 
followed by rapid and automated robotic microwave processing 
as a point to diversify compound collections in the second-part 
of the ‘machine’. Herein we report the establishment of a proof-
of-principle towards delivering such a machine for the 
preparation of a series of follow-on compounds. The Triptan 
drugs, an example sequence of follow-on compounds, used for 
the treatment of migraines, are a series of indole based 5-HT 
agonists. Sumatriptan was the first Triptan to market, delivered 
by Glaxo in 1991. Following this, further Triptan drugs were 
marketed for the treatment of different migraine types (Figure 
1).  
The synthesis of indoles has been of interest for many years due 
to their useful biological applications in the agrochemical and 
pharmaceutical industry.3 A broad number of indole syntheses 
are known, with the Fischer indole reaction remaining one of 
the most commonly used due its versatility. Indeed, the Fischer 
indole reaction is still employed in recent total syntheses and is 
currently the key heterocycle forming reaction for the 
commercial manufacture of the Triptan drugs. However, one of 
the main drawbacks, and perhaps one of the reasons for the 
plethora of alternative syntheses that have been developed, is 
the limited commercial availability of hydrazines. Owing to this 
drawback, other ways to access the key Fischer indole 
intermediate hydrazones and enhydrazines have been 
established, such approaches are often referred to as 
‘interrupted-Fischer’ syntheses. For example, the intermediate 
enhydrazines can be formed by a transition-metal catalyzed 
hydroamination of alkynes in a Larock-type synthesis with a 
variety of aromatic precursors.4 The derivatives of the 
intermediate hydrazones can be formed by a transition-metal 
catalyzed cross coupling of activated aromatics and a hydrazine 
starting material.5 Indoles can also be prepared in a modified 
Japp-KIingemann reaction.6 Alternatively the hydrazine can be 
formed prior to the Fischer Indole reaction either via an SNAr 
process between hydrazine and an appropriately activated 
aromatic or by the reduction of the corresponding diazonium 
salts.7  
In line with the latter approach, this project aims to use the 
continuous flow part of the hybrid machine to first prepare and 
then consume a diazonium salt. This will deliver an array of 
hydrazines on demand from their corresponding aniline input 
feeds (Scheme 1, Step 1). The emerging masked hydrazines will 
then be directly fed into the second part of the machine to 
undergo expedited Fischer indole reactions with a range of 
ketones and aldehydes using a robotic microwave reactor 
(Scheme 1, Step 2). The approach is modular in setup, where a 
common stream of hydrazine from Step 1 can be distributed to 
a range of microwave vials, prefilled with the required ketones 
or aldehydes, prior to microwave irradiation in Step 2. Such an 
approach takes advantage of the safe handling of unknown yet 
potentially hazardous materials under flow conditions before 
then being manipulated by automated equipment for the final 
part of the reaction. 
 
 
 
Results and Discussion 
In order to establish machine parameters for both the flow and 
microwave components, we started by exploring the 
microwave conditions for the Fischer indole reaction with the 
commercially available p-fluorophenyl hydrazine and 
cyclohexanone (Table 1). It was found that running this reaction 
for 10 minutes at 120 °C in acetonitrile solvent resulted in 97 % 
isolated yield (Table 1, entry 1). Next, the complex reaction 
mixture that would result from the in situ vitamin C reduction 
of a diazonium salt was tested for its performance in the indole 
formation under microwave conditions. When applying 
microwave irradiation for 10 minutes at 120 °C the yield was 
significantly lower than with pure hydrazine (15%, Table 1, 
entry 2), highlighting the difficulty of merging one multistep 
process directly into another. After screening of reaction 
temperature, equivalents of acid and equivalents of 
isoamylnitrite used to deliver the masked hydrazine, an 
improvement to 73% yield was acquired (Table 1, entry 8).  
With optimum conditions for merging the hydrazine generation 
with the microwave step in hand, the flow setup was designed 
to fit with this (Scheme 1). The flow part of the machine (Step 
1) consisted of merging of the aniline with hydrochloric acid in 
a T-piece and passage through a mixing coil of residence time τ1. This stream was then merged with a solution of 
isoamylnitrite and passed through a second reaction coil with 
the residence time τ2, where the diazonium salt was formed at 
0 °C. The resultant stream was merged with an ascorbic acid 
solution to induce reduction to the masked hydrazine, in the 
form of an oxalyl hydrazide, which could then be hydrolysed to 
the hydrazine in the presence of acid in the microwave step. To 
permit analysis and a measurement of effectiveness of the 
process, an aliquot of the exit stream was then transferred to a 
microwave vial and the Fisher reaction carried out to provide 
the indole. 
Table 1. Optimisation of Microwave Parameters, Step 2; 
isolated yields in parenthesis; batch hydrazine formation: 
1 mmol p-fluoroaniline, 1 mmol HCl, 1 mmol isoamylnitrite, 
1 mmol Vit C; a) 5 mmol of HCl; b) 1.2 mmol isoamylnitrite 
entry hydrazine TMW tMW
19F yield
source [°C] [min] [%]
1 commercial 120 10 98 (97)
2 in situ prepared 120 10 15
3 in situ prepared 140 10 30
4 in situ prepared 160 10 52 (47)
5 in situ prepared 180 10 46
6 in situ prepared 160 30 48
7a in situ prepared 160 10 67
8a,b in situ prepared 160 10 73
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Analysis of the 19F NMR with an internal standard served as a 
yield measure to guide the parameter optimization.  
During parameter screening the concentration of hydrochloric 
acid, isoamylnitrite and ascorbic acid, the temperature of the 
second reaction coil (diazonium salt formation) and the 
residence times in all reaction coils were screened. A selection 
of these results is shown in Scheme 1. Best conditions for the 
first step proved to be 1 M hydrochloric acid in H2O (5 equiv), 
0.24 M isoamylnitrite in MeCN (1.2 equiv), 0.2 M ascorbic acid 
in H2O (1 equiv), 0 °C in the second reaction coil, residence times 
of 0.6 min (τ1, 0.23 mL reaction coil), 3.3 min (τ2, 2 mL reaction 
coil) and 6.3 min (τ3, 5 mL reaction coil) at a flowrate of 
0.2 mL/min for each pump (Scheme 1, optimization table, entry 
10).  
Following reaction optimization, a small substrate scope of 
anilines was performed with cyclohexanone as the ketone 
partner. This reaction scoping also served to assess the 
robustness of the processing conditions against the propensity 
for blockage formation. Using the two-step machine-assisted 
process, 14 indoles were isolated in moderate to excellent 
yields over the four chemical reaction steps (Scheme 2). 
Notably, at the concentrations studied for the flow step, no 
blockages occurred across the screened substrates. The indole 
derived from p-chloroaniline (4) gave the highest yield of 74%. 
Strongly electron-withdrawing groups such as p-nitro or p-CF3 
groups (5, 8) produced lower yields (24%). This could be 
attributable to the competing radical formation with ascorbic 
acid, which is reportedly best with electron-poor aromatics.7i, j, 
m Ortho substituted anilines provided lower yields of the indoles 
than their corresponding para substituted anilines.  
A ketone/aldehyde substrate scope was then performed using 
p-fluoroaniline as partner to prepare a range of indoles (Scheme 
2). To achieve this, a common flow stream with the in situ 
prepared oxalyl hydrazide (Step 1) was transferred into a series 
of microwave vials preloaded with the desired carbonyl 
compound (or carbonyl precursor). Cyclic and acyclic ketones 
with varying chain lengths, benzylic ketones, aldehydes and 
acetals all participated in the reaction, affording the 
corresponding indoles in good to excellent yields over the four-
step process (31-68%, 15-22). Pleasingly, 4-dimethyl 
aminobutyraldehyde diethyl acetal, including a tertiary amine 
could be incorporated to give the desired indole in 60% yield 
(23). This is particularly notable in the context of the Triptan 
series, where this exact side-chain is present in several 
examples, Sumatriptan, Rizatriptan, Almotriptan and 
Zolmitriptan.  
 
entry c (HCl) c (isoamylnitrite) c (Vit C) T2 τ1 τ2 τ3
19F yield
[mol/L] [mol/L] [mol/L] [°C] [min] [min] [min] %
1 0.2 0.24 0.2 0 0.6 3.3 6.3 41
2 1 0.2 0.2 0 0.6 3.3 6.3 72
3 1 0.24 0.24 0 0.6 3.3 6.3 62
4 1 0.24 0.2 rt 0.6 3.3 6.3 53
5 1 0.24 0.2 0 5 3.3 6.3 60
6 1 0.24 0.2 0 0.6 1.7 6.3 64
7 1 0.24 0.2 0 0.6 8.3 6.3 65
8 1 0.24 0.2 0 0.6 3.3 2.5 64
9 1 0.24 0.2 0 0.6 3.3 12.5 64
10 1 0.24 0.2 0 0.6 3.3 6.3 74 (68)
Scheme 1. Outline of synthesis, machinery and optimization 
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After demonstrating the feasibility of the method over a range 
of both aniline and carbonyl substrates the machine was then 
used to prepare Zolmitriptan itself. Machine input feeds for this 
consisted of the appropriate oxazolidinone substituted aniline, 
Hydrocholoric acid, isoamyl nitrite, ascorbic acid and 4-dimethyl 
aminobutyraldehyde diethyl acetal and afforded the Triptan in 
56% yield. Following this demonstration a range of nine hitherto 
unreported analgoues of Zolmitriptan were synthetized in good 
to excellent yields (Scheme 3, 24-32). 
Conclusion 
In conclusion, we have designed a hybrid machine-assisted 
approach that incorporates a multistep continuous flow 
processes and robotic microwave reactors to expedite the rapid 
preparation of a library of indoles. This type of approach could 
be important for the screening and discovery of follow-on 
drugs. Key to realizing this ability was the optimization of the 
reaction conditions as the crude reaction mixture passed from 
one machine step to the next. In this manner 33 indoles, 
including nine analogues of the anti-migraine drug Zolmitriptan 
and Zolmitriptan itself, were synthesized. Notably, only ten of 
the examples presented here had been characterized in the 
literature prior to this report. The complexity of the equipment 
described here could be further advanced depending on desired 
capability and budget (see the Supporting Information for some 
proposed alterations). 
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